Answer
Hepatitis B virus can reactivate during Tagrisso (osimertinib mesylate) treatment and may cause fulminant hepatitis, hepatic failure or death.
Sources for this answer
- Tagrisso 40 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 32Document updated
Sources checked